Intrepid Advises Apostrophe on Its Sale to Hims & Hers Health

Intrepid announced today that it served as the exclusive financial advisor to Apostrophe, a leading teledermatology platform, on its sale to Hims & Hers Health, Inc. (NYSE: HIMS) (Hims & Hers).

Founded in 2012 and based in Oakland, Calif., Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized direct-to-consumer skincare brand, and visionary leadership team, the company has experienced rapid growth over the past several years.

Based in San Francisco, Calif., Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.

Ben Holber, Co-Founder and CEO of Apostrophe, commented: “We are thrilled to have completed this transaction with Hims & Hers, which brings together two leaders in telehealth with a shared passion for and commitment to the patient. Being part of the Hims & Hers family will allow Apostrophe to touch even more lives for the better, continue to scale, and bring customized telehealth solutions to the forefront of care where it belongs. The Intrepid team was there for us every step of the way and was a trusted source of advice as we navigated this process. Intrepid’s Healthcare and Beauty & Personal Care teams were a great fit, they truly understood the benefits of our telehealth pharmacy platform coupled with our compelling direct-to-consumer branded experience. Intrepid helped convey our exciting story and growth potential to deliver a truly exceptional outcome.”

“We are excited to announce that these two powerful and impactful brands are joining forces in the direct-to-consumer space, and are grateful to have played a role in the Apostrophe journey,” said Mike Garcia, Managing Director in Intrepid’s Beauty & Personal Care practice. Adam Abramowitz, Managing Director and Co-Head of the Healthcare practice at Intrepid, added: “The Apostrophe telehealth platform and brand sit at the intersection of several powerful themes within the consumer and healthcare spaces. We are proud to have leveraged the strong combination of Intrepid’s Healthcare and Beauty & Personal Care practices to assist the Apostrophe team in this exciting transaction. We are eager to see what the Apostrophe and Hims & Hers teams will accomplish together in their next phase of growth.”

About Intrepid’s Healthcare Group

Intrepid’s Healthcare Group is dedicated to providing strategic advice to businesses in healthcare services across a range of delivery settings and provider specialties; outsourced services including healthcare IT, staffing and revenue cycle management; and life sciences tools and services encompassing diagnostics and clinical trial services.  We maintain extensive relationships with strategic buyers and financial sponsors across these sectors and have helped various middle-market companies realize an optimal value with various forms of financing and M&A initiatives.

About Intrepid’s Beauty & Personal Care Practice

Intrepid provides dedicated merger and acquisition advisory and capital raising services to the Beauty & Personal Care industry. By focusing exclusively on beauty care companies, our industry bankers have a deep understanding of trends and value-drivers across the sector and maintain ongoing dialogue with the acquirer and investor universe. Our Beauty & Personal Care practice has a proven track record of helping clients sell to global strategic acquirers and value-added private equity groups across the beauty and personal care landscape.

Investment banking services offered by Intrepid Investment Bankers LLC, a subsidiary of MUFG Union Bank. Member FINRA/SIPC